Relmada Therapeutics (RLMD) Free Cash Flow (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Free Cash Flow data on file, last reported at -$15.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 16.6% year-over-year to -$15.1 million in Q1 2026; TTM through Mar 2026 was -$42.8 million, a 24.65% increase from a year earlier, with the FY2025 full-year figure at -$45.8 million, up 11.53% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$15.1 million, down from -$14.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for RLMD reached as high as -$6.4 million in Q2 2025 and fell as low as -$35.9 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$15.8 million across 5 years, with a median of -$14.6 million in 2025.
• Across the five-year window, Free Cash Flow jumped 71.44% in 2023 and slumped 65.87% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$35.9 million in 2022, then soared by 71.44% to -$10.2 million in 2023, then advanced by 14.15% to -$8.8 million in 2024, then tumbled by 65.87% to -$14.6 million in 2025, then slipped by 3.23% to -$15.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$15.1 million in Q1 2026, -$14.6 million in Q4 2025, and -$6.7 million in Q3 2025.